The frequency of co-mutations of KEAP1 and KRAS in lung cancers, which further increases treatment resistance [23] and decreases survival [22], adds to the importance of addressing the biologic complexity and immune regulation by these tumors. This evidence concerns the gene KRAS and lung carcinoma.